0
Editorials |

So Many Drugs, So Little Time : The Future Challenge of Cystic Fibrosis Care

Michael P. Boyle, MD, FCCP
Author and Funding Information

Affiliations: Baltimore, MD
 ,  Dr. Boyle is Assistant Professor of Medicine, the Johns Hopkins University School of Medicine, and is Director, the Johns Hopkins Adult Cystic Fibrosis Program.

Correspondence to: Michael P. Boyle, MD, FCCP, Assistant Professor of Medicine, Director, Adult Cystic Fibrosis Program, Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Jefferson B1–170, 600 N Wolfe St, Baltimore, MD 21287-8922; e-mail: mboyle@jhmi.edu



Chest. 2003;123(1):3-5. doi:10.1378/chest.123.1.3
Text Size: A A A
Published online

Extract

After the identification of the cystic fibrosis (CF) gene in 19891 and the emergence of gene therapy in the early 1990s, great hope existed that a cure for CF could be developed rapidly. The last decade has led to the realization that while a cure for CF is still the long-term goal, more immediate gains may be made by developing therapies that target the chronic cycle of infection and inflammation that drives the progressive lung disease seen in CF.2 Therapies that improve or correct the abnormal ion transport that is characteristic of the respiratory epithelium in CF may also eventually be effective in slowing the progression of CF lung disease. Numerous new therapeutic agents targeting these areas are in development. Many are currently in clinical trials being conducted by the Cystic Fibrosis Foundation Therapeutics Development Network (CFF-TDN), a national multicenter network that has been designed specifically to accelerate the development of new therapeutic agents for the treatment of CF.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543